The facility in Hangzhou will package Merck medicines for China and the Asia-Pacific region.
Merck, known as MSD outside of the United States and Canada, opened a facility in Hangzhou, China to package Merck medicines for China and the Asia Pacific region, announced the company in an April 16, 2013 press release. The facility, a nearly $120-million investment by Merck, is located in the Hangzhou Economic and Technology Area (HEDA).
Merck also has an R&D Center in Beijing, three manufacturing facilities throughout the country, a marketing and sales organization headquartered in Shanghai, and employs more than 5000 employees in China. The healthcare system in China is growing rapidly, notes the company. In 2011, Merck established its Asia R&D headquarters in Beijing and committed to invest more than $1.5 billion in R&D in China over the next five years.
The new 75,000-m2 facility is capable of holding up to 16 high-speed lines to package pharmaceutical tablets and sterile Merck medicines that are used to manage diabetes, cardiovascular, infectious, respiratory, and bone diseases. Packaging capacity is currently estimated at more than 300 million packages annually. Products used in Merck’s clinical studies and in its commercial activities to support future new product launches also will be packaged at the new HEDA plant. The HEDA facility received a cGMP certification in January 2013. The facility was constructed with consideration for the environment; special air, waste, and water-management procedures and systems were built into the facility, notes the company.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.